Alpine Immune Sciences, Inc. (ALPN)
Stock Price:
$8.01 USD
0.00 (0.00%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
190.52M |
| Revenue (ttm) |
2.95M |
| Net Income (ttm) |
-33.08M |
| Shares Out |
23.78M |
| EPS (ttm) |
-1.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$8.01 |
| Previous Close |
$8.01 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
8.01 |
| Day's Range |
7.81 - 8.34 |
| Day's Volume |
33,767 |
| 52-Week Range |
2.05 - 15.00 |
More Stats
| Market Cap |
190.52M |
| Enterprise Value |
122.24M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.78M |
| Float |
12.61M |
| EPS (basic) |
-1.78 |
| EPS (diluted) |
-1.78 |
| FCF / Share |
1.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
14.54% |
| Payout Ratio |
n/a |
| Shares Short |
26,841 |
| Short Ratio |
0.41 |
| Short % of Float |
0.21% |
| Beta |
1.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
6.88 |
| PS Ratio |
64.54 |
| PB Ratio |
12.78 |
| Revenue |
2.95M |
| Operating Income |
-34.04M |
| Net Income |
-33.08M |
| Free Cash Flow |
27.70M |
| Net Cash |
68.28M |
| Net Cash / Share |
2.87 |
| Gross Margin |
-1,155.39% |
| Operating Margin |
-1,153.25% |
| Profit Margin |
-1,120.50% |
| FCF Margin |
938.48% |
| ROA |
-24.63% |
| ROE |
-107.30% |
| ROIC |
-89.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.50*
(168.41% upside)
Low
18.0
Current: $8.01
High
27.0
Target: 21.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 1.74 | 0.71 | 1.73 | 2.95 | 0.49 | - | - | - |
| Revenue Growth | 146.81% | -59.27% | -41.32% | 499.59% | - | - | - | - |
| Gross Profit | 1.74 | 0.71 | 1.73 | 2.95 | 0.49 | - | - | - |
| Operating Income | -43.57 | -36.63 | -14.97 | -1.19 | -0.37 | -14.49 | -15.28 | -8.88 |
| Net Income | -41.85 | -36.49 | -7.78 | -1.23 | -0.37 | -14.66 | -16.20 | -9.57 |
| Shares Outstanding | 18.36 | 13.85 | 6.48 | 0.56 | 0.50 | 0.18 | 0.04 | 0.03 |
| Earnings Per Share | -2.28 | -2.63 | -1.20 | -2.18 | -0.74 | -81.08 | -418.00 | -278.80 |
| Operating Cash Flow | -35.35 | -28.42 | -16.57 | -3.80 | 4.82 | -14.45 | -14.29 | -9.52 |
| Capital Expenditures | -0.82 | -0.50 | -0.59 | -0.78 | -0.01 | - | -0.13 | -0.03 |
| Free Cash Flow | -36.17 | -28.91 | -17.16 | -4.58 | 4.81 | -14.45 | -14.42 | -9.55 |
| Cash & Equivalents | 40.65 | 52.30 | 81.37 | 11.82 | 87.25 | 27.81 | 3.60 | - |
| Total Debt | 16.36 | 4.20 | 5.03 | 0.11 | - | - | 15.34 | - |
| Net Cash / Debt | 24.30 | 48.10 | 76.34 | 11.71 | 87.25 | 27.81 | -11.75 | - |
| Assets | 54.09 | 54.87 | 85.22 | 12.60 | 87.91 | 28.54 | 4.13 | - |
| Liabilities | 24.62 | 10.28 | 6.31 | 2.52 | 4.42 | 44.30 | 17.63 | - |
| Book Value | 29.47 | 44.59 | 78.92 | -1.46 | 83.49 | -15.75 | -91.29 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Alpine Immune Sciences, Inc. |
| Country |
United States |
| Employees |
53 |
| CEO |
Mitchell H. Gold |
Stock Information
| Ticker Symbol |
ALPN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALPN |
Description
Alpine Immune Sciences focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.